Challenges in the Diagnosis of Neuroendocrine Tumors

Video

For High-Definition, Click

When referred to academic centers, many patients who have been diagnosed with a neuroendocrine tumor (NET) have received a broad assortment of tests and assays. In general, Rodney F. Pommier, MD notes, the first task when seeing these patients is to narrow down the information based on clinical parameters.

To determine diagnosis patterns, Pommier analyzed 150 patients with abdominal carcinoids. Out of these patients, only 3.5% of patients were referred 3 months following their initial presentation. The remaining 96.5% of patients received a diagnosis on average 6.5 years after presentation and even up to 20 years in some cases. In general, these patients receive 35 different initial diagnoses.

This delay, Pommier feels, may be related to the fact that community physicians are not initially thinking about carcinoids as a potential diagnosis. This is due to a combination of the natural characteristics of the disease and a lack of general awareness.

Related Videos
In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
In this sixth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss potential opportunities to leverage artificial intelligence tools in cancer screening, diagnosis, staging, and prognosis.
Christopher M. Gallagher, MD
A panel of 6 experts on breast, lung, and gastrointestinal cancers
Shridar Ganesan, MD, PhD
In this fifth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss the need for evidence to support the utilization of different artificial intelligence tools in healthcare.
A panel of 6 experts on breast, lung, and gastrointestinal cancers
A panel of 6 experts on breast, lung, and gastrointestinal cancers
Alan Tan, MD
Haejin In, MD, MPH, MBA, FACS, FSSO